Feedback / Questions
dectrekumab (QAX576) - Novartis
Novartis: Q3 2013 Results
(Novartis)
-
Oct 24, 2013 -
Anticipated regulatory submission for allergic diseases in 2017 or after
Anticipated regulatory
•
Immunology
http://www.novartis.com/downloads/investors/financial-results/quarterly-results/q3-2013-ir-presentation.pdf
Oct 24, 2013
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
.